RTGNOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. is a U.S.-based medical technology company organized around the development of ophthalmic products and procedures for retinal disease. The company is structured as a development-stage enterprise focused on bringing retinal diagnostics and treatment-related technologies to market.

Kysy yhtiöstä
Nettotulos−2,4milj. USD
+43,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

01milj. USD2020202120242025
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Retinal diagnostics40 %

Technologies intended to detect, evaluate, or monitor retinal disease.

Ophthalmic treatment devices35 %

Devices and tools used in retinal or eye-care procedures.

Product development services15 %

Internal development work to advance ophthalmic technologies toward market.

Regulatory and commercialization support10 %

Activities related to product approval, launch preparation, and market entry.

Asiakkaat

The company’s end customers are expected to be eye-care professionals, ophthalmology practices, and medical institutions that diagnose or treat retinal conditions. Its products would also be relevant to distributors and commercial partners involved in bringing ophthalmic devices to market. Because the business is development-stage, customer demand is tied to regulatory approval, clinical adoption, and reimbursement acceptance.

Ophthalmology practices

Buy retinal diagnostics or treatment tools to support clinical eye-care workflows.

Hospitals and surgical centers

Use ophthalmic devices in procedural settings for retinal care.

Distributors and channel partners

Help commercialize and place products into eye-care markets.

Clinical and research institutions

Evaluate new retinal technologies for validation and adoption.

Strategia

The company’s strategic focus is to complete product development and move retinal technologies toward regulatory approval and commercialization. Its business model depends on converting development assets into marketable ophthalmic products, which makes execution on validation, approval, and launch the central priority.

Product development completionLyhyt aikaväli

The company must finish development before it can generate commercial demand.

Regulatory approvalLyhyt aikaväli

Medical devices require clearance or approval before broad commercialization.

Commercialization build-outKeskipitkä aikaväli

Adoption by clinicians and institutions determines whether the platform can scale.

Maantiede

RetinalGenix Technologies Inc. is headquartered in the United States and appears to operate primarily from a U.S. corporate base. The available filings do not disclose meaningful country revenue breakdowns, so the business profile is best understood as U.S.-centered with potential future exposure to regulated healthcare markets beyond the United States.

Riskit

The company is exposed to development-stage execution risk, including the possibility that products do not reach commercialization or fail to gain clinical acceptance. It also faces financing, internal control, and regulatory risks that are common for early-stage medical device companies and can materially affect operations and reporting.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going concern and financing risk1No commercial revenue2Regulatory approval risk3Internal control weakness4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea

    Development-stage companies need external capital to fund operations and product development.

    Kohdistuu: Liquidity and continuity of operations

  2. No commercial revenueVaikutus: KorkeaTodennäköisyys: Korkea

    The company has not yet generated sales, so value depends on future product launch success.

    Kohdistuu: Entire business model

  3. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea

    Ophthalmic devices typically require regulatory clearance before commercialization.

    Kohdistuu: Product launch timeline

  4. Internal control weaknessVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Management disclosed ineffective internal controls and a material weakness from lack of segregation of duties.

    Kohdistuu: Financial reporting reliability

  5. Clinical adoption and reimbursement riskVaikutus: Keskitaso

    Even approved medical products may face slow uptake if benefits are not compelling or reimbursement is limited.

    Kohdistuu: Commercialization success

Kirjanpito

Harkinnanvaraiset erät
Going concern assessment

Cash resources and funding needs determine whether the company can continue operations.

Vaikutus: Affects disclosure, valuation, and solvency analysis

Internal control over financial reporting

Management disclosed ineffective controls and a material weakness from lack of segregation of duties.

Vaikutus: Raises risk of misstatement and audit scrutiny

Equity financing and share issuance

The company has relied on stock issuance to fund operations.

Vaikutus: Can dilute shareholders and affect per-share metrics

Development-stage expense recognition

Product development and launch preparation costs are typically recognized as expenses as incurred.

Vaikutus: Suppresses near-term earnings until commercialization

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Genprex, Inc.

GNPX · Pharmaceutical Preparations

IRIDEX Corporation

IRIX · Electromedical & Electrotherapeutic Apparatus

Ocugen, Inc.

OCGN · Biological Products, (No Diagnostic Substances)

Oragenics Inc

OGEN · Pharmaceutical Preparations

MeiraGTx Holdings plc

MGTX · Biological Products, (No Diagnostic Substances)

Ventyx Biosciences, Inc.

Pharmaceutical Preparations

Päivitetty: 24.9.2026